AVI BioPharma names chief executive

Chris Garabedian joins US biopharmaceutical firm from Celgene

Chris Garabedian will become chief executive and president of AVI BioPharma on 1 January 2011.

Garabedian, who has been a director of the Bothell, Washington-based biopharmaceutical firm since June, will continue as a member of the board. David Boyle, who held the post of interim ceo and president, will continue in his role as chief financial officer and senior vice president.

Garabedian brings to AVI broad biotechnology and pharmaceutical experience. He has been vice president of corporate strategy at Celgene since July 2007. Before this, he held several key roles at Gilead Sciences between 1997 and 2005, including vice president of corporate development, vice president of marketing and vice president of medical affairs.

He also held various commercial and product development roles at COR Therapeutics and Abbott Laboratories and began his career as a consultant to the pharmaceutical industry.

‘We believe Chris' experience is ideal for driving products from early development through commercialisation, while also leveraging business development opportunities to unlock further value from our RNA-based therapeutics technology platforms,’ said William Goolsbee, AVI's chairman.

You may also like

Pharmaceutical

PharmNovo enhances its board ahead of Phase II development

The new board members bring complementary experience in drug development, clinical execution and partnering, supporting the company’s continued progress and dialogue with potential partners
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Finance

Moderna partners with Recordati to commercialise propionic acidemia mRNA therapy

The pair have entered a strategic collaboration to advance and globally commercialise its investigational propionic acidemia treatment mRNA-3927, with Moderna leading clinical development and manufacturing and Recordati responsible for worldwide commercialisation
Finance

AstraZeneca strengthens weight management pipeline with CSPC Pharmaceuticals collaboration

The pair have signed a strategic collaboration covering eight obesity and type 2 diabetes programmes, including a clinical-ready GLP-1/GIP asset, AI-driven peptide discovery capabilities and injectable dosing technology
Finance

Ardena divests Södertälje API site to Nanologica

The divestment of the company's drug substance manufacturing site in Sweden to Nanologica is part of a strategic move to focus investment on specialised CDMO capabilities supporting precision medicines
Pharmaceutical

New research suggests repurposed diabetic drug may help prostate cancer

A class of medication called SGLT2 inhibitors, traditionally used for diabetes, may help slow prostate cancer progression in men receiving hormone treatment
Drug Delivery

Indonesia looks to oral GLP-1s as it battles rising obesity

Novo Nordisk's oral GLP-1 therapy for chronic weight management could help the country deliver injectable-comparable weight loss alongside cardiovascular risk-reduction benefits for its expanding population
Subscribe now